Enovis Co. (NYSE:ENOV) Shares Bought by Kelly Lawrence W & Associates Inc. CA

Kelly Lawrence W & Associates Inc. CA boosted its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 5.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 272,393 shares of the company's stock after acquiring an additional 13,100 shares during the quarter. Enovis comprises about 2.8% of Kelly Lawrence W & Associates Inc. CA's investment portfolio, making the stock its 14th biggest position. Kelly Lawrence W & Associates Inc. CA owned 0.48% of Enovis worth $11,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ENOV. Confluence Investment Management LLC bought a new stake in shares of Enovis during the 4th quarter worth approximately $3,494,000. Geode Capital Management LLC boosted its stake in shares of Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after purchasing an additional 80,165 shares during the period. UMB Bank n.a. grew its holdings in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Enovis by 19.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock worth $677,000 after buying an additional 2,518 shares during the period. Finally, FMR LLC lifted its holdings in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after buying an additional 484 shares in the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Stock Down 0.2 %

Shares of NYSE:ENOV traded down $0.06 during trading hours on Friday, hitting $35.07. The company's stock had a trading volume of 419,652 shares, compared to its average volume of 746,761. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm's fifty day moving average price is $36.70 and its 200 day moving average price is $41.98. Enovis Co. has a 52 week low of $29.32 and a 52 week high of $56.43. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -16.01 and a beta of 1.86.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. As a group, research analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 target price on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.